KR100761652B1 - 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 - Google Patents
단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 Download PDFInfo
- Publication number
- KR100761652B1 KR100761652B1 KR1020010051528A KR20010051528A KR100761652B1 KR 100761652 B1 KR100761652 B1 KR 100761652B1 KR 1020010051528 A KR1020010051528 A KR 1020010051528A KR 20010051528 A KR20010051528 A KR 20010051528A KR 100761652 B1 KR100761652 B1 KR 100761652B1
- Authority
- KR
- South Korea
- Prior art keywords
- peg
- protein
- peptide
- molecular weight
- polymer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols
- C08G65/40—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives derived from phenols from phenols (I) and other compounds (II), e.g. OH-Ar-OH + X-Ar-X, where X is halogen atom, i.e. leaving group
- C08G65/4012—Other compound (II) containing a ketone group, e.g. X-Ar-C(=O)-Ar-X for polyetherketones
- C08G65/4031—(I) or (II) containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Abstract
Description
고분자 유도체의 종류 | 생물학적 활성 | T1/2 |
인터페론 | 100 | 3.7 |
mPEG(MW 10,000) | 38 | 15.4 |
Di-PEG(MW 20,000) | 12 | 23.3 |
Tri-PEG(MW 30,000) | 6.2 | 32.5 |
Tetra-PEG(MW 33,400) | 10.3 | 36.5 |
Tetra-PEG(MW 35,000) | 11 | 37 |
Tetra-PEG(MW 40,000) | 10.5 | 40.2 |
mPEG(MW 20,000) | 32 | 18.2 |
Di-PEG(MW 40,000) | 7 | 33.8 |
Tri-PEG(MW 60,000) | 3 | 42.1 |
Tetra-PEG(MW 63,400) | 6.5 | 43.3 |
Tetra-PEG(MW 65,000) | 6.2 | 43.5 |
Tetra-PEG(MW 70,000) | 7.1 | 44.9 |
Claims (12)
- 제 1항에 있어서, 상기 Z는 COONHS 또는 CONH-CH2CH2(OCH2CH2) n4OCOONHS며, 이 때, n4가 50∼500사이의 정수값인 것을 특징으로 하는 생리적으로 고활성인 고분자 유도체.
- 제 1항에 있어서, n1, n2 및 n3가 200∼500의 정수값인 것을 특징으로 하는 생리적으로 고활성인 고분자 유도체.
- 제 2항에 있어서, n4가 50∼250의 정수값인 것을 특징으로 하는 생리적으로 고활성인 고분자 유도체.
- 제 1항에 있어서, 단위 폴리에틸렌 글리콜이 라이신-라이신(Lys-Lys-HCl)에 의해 3개가 연결된 것을 특징으로 하는 생리적으로 고활성인 고분자 유도체.
- 제 1항의 활성화된 생체적합성 고분자 유도체에 단백질 또는 펩타이드가 결합된 단백질-고분자 또는 펩타이드-고분자 접합체.
- 제 6항에 있어서, 상기 단백질 또는 펩타이드:고분자 유도체의 반응 몰비가 약 1:1에서 1:50인 것을 특징으로 하는 접합체.
- 제 6항에 있어서, 상기 단백질 또는 펩타이드:고분자 유도체의 반응 몰비가 약 1:5에서 1:20인 것을 특징으로 하는 접합체.
- 제 6항에 있어서, 단백질 또는 펩타이드와 고분자의 결합에서 펩타이드 내 결합부위는 라이신의 아민기나 N-말단인 것을 특징으로 하는 접합체
- 제 6항에 있어서, 단백질 또는 펩타이드는 인터페론 알파, 베타, 감마(Interferon -α, -β or -γ), 염기성 섬유아세포 성장 인자(basic fibroblast growth factor, bFGF) 또는 호중구 생성 자극 인자(granulocyte colony stimulating factor, G-CSF)중 하나를 특징으로 하는 접합체.
- 제 6항에 있어서, 접합체는 인터페론 알파와 고분자 유도체의 접합체인 것을 특징으로 하는 접합체.
- 제 11항에 의한 접합체 및 치료적으로 불활성인 담체를 포함하는 인터페론 감수성 질환 치료용 또는 예방용 약학적 조성물.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010051528A KR100761652B1 (ko) | 2001-08-25 | 2001-08-25 | 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010051528A KR100761652B1 (ko) | 2001-08-25 | 2001-08-25 | 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030017908A KR20030017908A (ko) | 2003-03-04 |
KR100761652B1 true KR100761652B1 (ko) | 2007-10-04 |
Family
ID=27720856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010051528A KR100761652B1 (ko) | 2001-08-25 | 2001-08-25 | 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100761652B1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
KR20020010363A (ko) * | 2000-07-29 | 2002-02-04 | 박명옥 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
US6566506B2 (en) * | 1993-10-27 | 2003-05-20 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
-
2001
- 2001-08-25 KR KR1020010051528A patent/KR100761652B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566506B2 (en) * | 1993-10-27 | 2003-05-20 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
KR20020010363A (ko) * | 2000-07-29 | 2002-02-04 | 박명옥 | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 |
Also Published As
Publication number | Publication date |
---|---|
KR20030017908A (ko) | 2003-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100396983B1 (ko) | 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체 | |
US9364553B2 (en) | Synergistic biomolecule-polymer conjugates | |
EP1039922B1 (en) | Improved interferon polymer conjugates | |
Pasut et al. | Protein, peptide and non-peptide drug PEGylation for therapeutic application | |
US7201897B2 (en) | Interferon conjugates | |
EP0247860B1 (en) | Tumor necrosis factor formulation and its preparation | |
US6436386B1 (en) | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers | |
EP1075282B1 (en) | Peg-lhrh analog conjugates | |
US8372422B2 (en) | Hydroxyapatite-targeting poly(ethylene glycol) and related polymers | |
WO1994028024A1 (en) | Carbohydrate-modified polymer conjugates with erythropoietic activity | |
HUT75533A (en) | Improved interferon polymer conjugates | |
ZA200105932B (en) | GCSF conjugates. | |
CA2720306C (en) | Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof | |
US20030103934A1 (en) | Drugs having long-term retention in target tissue | |
US8629104B2 (en) | G-CSF and water-soluble polymer conjugate | |
KR100761652B1 (ko) | 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체 | |
KR100888371B1 (ko) | 가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제 | |
KR20030076417A (ko) | 생체적합성 고분자가 시스테인 잔기에 화학양론적으로결합된 g-csf의 제조 방법 | |
KR100480432B1 (ko) | G-csf와 폴리에틸렌글리콜 유도체의 배합체 | |
JPWO2003000278A1 (ja) | 軟膏剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121231 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141211 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161222 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181217 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191126 Year of fee payment: 14 |